2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Daniel P. Petrylak, MD, discusses the utility of tissue biopsy versus liquid biopsy in prostate cancer.
Daniel P. Petrylak, MD, professor of medicine and urology and co-leader of Cancer Signaling Networks with Yale Cancer Center, as well as a 2017 Giant of Cancer Care® in Genitourinary Cancers, discusses the utility of tissue biopsy versus liquid biopsy in prostate cancer.
Tissue-based and liquid-based testing assays offer different advantages and disadvantages. However, tissue testing is preferrable in most scenarios, according to Petrylak.
Tissue testing allows a comprehensive view of the mutations and heterogeneity of the tumor, Petrylak says. Conversely, liquid biopsy may offer more homologous findings that show whether a tumor expresses a particular mutation.
However, tissue-based bone biopsy in prostate cancer remains a challenge.
Currently, biomarkers such as DNA repair mutations are used to inform treatment. Additionally, prostate-specific membrane antigen and androgen receptor mutations serve as more investigational biomarkers for targeted therapy, concludes Petrylak.